AGC Biologics Opens New Facility in Søborg, Denmark

AGC Biologics, a renowned contract development and manufacturing organization (CDMO), has announced the commencement of operations at its newly constructed facility in Søborg, Denmark. The opening of this facility marks the culmination of a year-long construction process. The new plant is expected to enhance the company’s capacity to develop and manufacture biopharmaceuticals for their global client base.

This development comes as part of AGC Biologics’ strategic expansion to cater to the growing demand in the biopharmaceutical sector. According to a statement released by the company, the Søborg facility is equipped with state-of-the-art technology and is aimed at enhancing production capabilities to meet customer needs efficiently.

The completion and operation of the new factory are significant milestones for AGC Biologics, which has seen increased demand for its services during the global health crisis. The company has been involved in the production of various vaccines and therapeutic products, positioning itself as a critical player in addressing international healthcare challenges.

“Our new Søborg facility is a testament to our commitment to expand and innovate within the biopharmaceutical manufacturing sector,” said a spokesperson from AGC Biologics. “We are excited to begin operations and continue to provide high-quality solutions for our clients.”